Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
Daiichi Sankyo
Johnson and Johnson
Accenture
US Department of Justice
UBS
Merck
Fuji

Generated: February 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLMESARTAN MEDOXOMIL

« Back to Dashboard

Clinical Trials for Olmesartan Medoxomil

Trial ID Title Status Sponsor Phase Summary
NCT00134160 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed Japan Heart Foundation Phase 4 The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.
NCT00134160 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed OSCAR Study Phase 4 The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.
NCT00139698 Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Completed Pfizer Phase 3 Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
NCT00151775 Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure Completed Daiichi Sankyo Inc. Phase 2/Phase 3 This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.
NCT00151814 Olmesartan Pediatric Pharmacokinetic (PK) Study Completed Daiichi Sankyo Inc. Phase 1 Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years
NCT00151827 Olmesartan Medoxomil in Hypertension and Renal Impairment Completed Sankyo Pharma Gmbh Phase 3 This is a study in hypertensive patients with mild to moderate renal impairment. The antihypertensive efficacy of olmesartan medoxomil is compared to losartan.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Olmesartan Medoxomil

Condition Name

Condition Name for Olmesartan Medoxomil
Intervention Trials
Hypertension 26
Essential Hypertension 21
Healthy 6
Healthy Subjects 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olmesartan Medoxomil
Intervention Trials
Hypertension 43
Kidney Diseases 4
Atherosclerosis 3
Cardiovascular Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olmesartan Medoxomil

Trials by Country

Trials by Country for Olmesartan Medoxomil
Location Trials
United States 367
Germany 24
Netherlands 12
Mexico 11
Poland 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olmesartan Medoxomil
Location Trials
California 17
Florida 16
Texas 15
Ohio 15
North Carolina 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olmesartan Medoxomil

Clinical Trial Phase

Clinical Trial Phase for Olmesartan Medoxomil
Clinical Trial Phase Trials
Phase 4 22
Phase 3 34
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olmesartan Medoxomil
Clinical Trial Phase Trials
Completed 58
Recruiting 5
Terminated 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olmesartan Medoxomil

Sponsor Name

Sponsor Name for Olmesartan Medoxomil
Sponsor Trials
Daiichi Sankyo Inc. 23
Daiichi Sankyo Europe, GmbH 9
Sankyo Pharma Gmbh 7
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olmesartan Medoxomil
Sponsor Trials
Industry 68
Other 8
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
US Department of Justice
Deloitte
McKesson
Teva
Baxter
Express Scripts
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.